Diurnal Variation of Plasminogen Activator Inhibitor-1

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Metabolic Syndrome X
Interventions
DRUG

Eplerenone (Morning)

"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."

DRUG

Eplerenone (Night-time)

Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg

Trial Locations (1)

37232-8802

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

lead

Vanderbilt University Medical Center

OTHER

NCT00515021 - Diurnal Variation of Plasminogen Activator Inhibitor-1 | Biotech Hunter | Biotech Hunter